Dry eye is a multifactorial disease characterized by a loss of homeostasis of the tear film layer, which can present itself in different ways. Dry Eye Awareness Month is dedicated ...

As the number of actionable biomarkers in thoracic oncology continues to grow, the role of the multidisciplinary care team evolves to ensure patients receive comprehensive biomarker testing and ...

Workforce expansion authorized after the 2024 Harlem outbreak remains incomplete, with 35 staff onboard versus a planned 56, leaving gaps in inspection and response throughput. A second lethal cluster ...

Dermatology offices spend ~13 hours weekly on prior authorizations, file ~39 requests per physician annually, and see roughly one-third denied, creating operational costs and delayed initiation of ...

Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal. Patients with stage 2 and ...

Use of automated insulin delivery technology improves a Healthcare Effectiveness Data and Information Set quality measure in ...

Mean LDL-C at 6 months was 76.3 vs 85.6 mg/dL, yielding an adjusted difference of −6.62 mg/dL and higher attainment of LDL-C <50 mg/dL. Intervention uptake increased intensive and combination ...

Urs Weber, MD, discusses why comprehensive NGS is critical and where community biomarker testing often falls short.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and ...

FDA approved zidesamtinib for previously treated ROS1+ locally advanced/metastatic NSCLC, marking GSK’s entry into approved lung cancer therapeutics following acquisition of Nuvalent’s portfolio. ROS1 ...

A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...

CARDIO-TTRansform randomized 1432 wild-type or hereditary ATTR-CM patients to eplontersen 45 mg vs placebo every 4 weeks, with a primary composite endpoint assessed through week 140. Real-world ...